The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Restricted access

Guidelines for management of patients with myelodysplastic syndromes (MDS) have been generated by the National Comprehensive Cancer Network (NCCN) Myelodysplastic Syndromes Panel. Because MDS is a heterogeneous spectrum of disorders, these patients have been categorized into prognostic subgroups, predominantly using the International Prognostic Scoring System (IPSS). Several drugs have been used to treat these patients, and their selection and sequential recommended use by the panel depend on disease characteristics and responses to treatment. Recombinant erythropoietin alfa and darbepoetin alfa have been the mainstay of therapy for treating anemia associated with MDS. The FDA has recently approved several other drugs for treating MDS, including azacytidine and decitabine for all stages of disease, lenalidomide for low-risk anemic patients with del(5q) chromosomal abnormality, and deferasirox for treating iron overload. For iron chelation, deferoxamine is also used occasionally. Treatment with immunosuppressive therapy (antithymocyte globulin and cyclosporin) has been therapeutically beneficial for a subset of younger patients with MDS. Because the financial cost of these therapies are substantial and have received only limited attention, this article evaluates the costs of specific drugs and their sequential use in the lower-risk IPSS (low and intermediate-1) subgroups based on the NCCN guidelines. Results estimate an average annual cost for potentially anemia-altering drugs of $63,577 per patient, ranging from $26,000 to $95,000, depending on the specific therapies. In patients for whom the therapies fail, annual costs for iron chelation plus red blood cell transfusions are estimated to average $41,412. The economic impact of drug therapy should be weighed against the patient's potential for improvement in clinical outcomes, quality of life, and transfusion requirements.

Correspondence: Peter Greenberg, MD, Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305-5821. E-mail: peterg@stanford.edu
  • 1.

    GreenbergPL. Clinical and prognostic characterization of myelodysplastic syndromes. In: Greenberg PL ed.Myelodysplastic Syndromes: Clinical and Biological Advances. 1st ed.Cambridge: Cambridge University Press; 2006:132.

    • Search Google Scholar
    • Export Citation
  • 2.

    GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood1997;89:20792088.

  • 3.

    GreenbergPLBennettJMBloomfieldCD. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1, 2004. J Natl Compr Canc Netw2003;1:456471.

    • Search Google Scholar
    • Export Citation
  • 4.

    GreenbergPBattiwallaMBennettJ. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 12009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 15 2008.

    • Search Google Scholar
    • Export Citation
  • 5.

    Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:6771.

    • Search Google Scholar
    • Export Citation
  • 6.

    NegrinRSSteinRVardimanJ. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood1993;82:737743.

    • Search Google Scholar
    • Export Citation
  • 7.

    GotlibJGreenbergPL. Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy. In: Greenberg PL ed.Myelodysplastic Syndromes: Clinical and Biological Advances. 1st ed.Cambridge: Cambridge University Press; 2006:209242.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:6875.

    • Search Google Scholar
    • Export Citation
  • 9.

    Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344351.

    • Search Google Scholar
    • Export Citation
  • 10.

    CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321327.

    • Search Google Scholar
    • Export Citation
  • 11.

    MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204209.

    • Search Google Scholar
    • Export Citation
  • 12.

    MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513519.

    • Search Google Scholar
    • Export Citation
  • 13.

    SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol2002;20:24292440.

    • Search Google Scholar
    • Export Citation
  • 14.

    KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:17941803.

    • Search Google Scholar
    • Export Citation
  • 15.

    ListADewaldGBennettJ. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med2006;355:14561465.

  • 16.

    PorterJGalanelloRSaglioG. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol2008;80:168176.

    • Search Google Scholar
    • Export Citation
  • 17.

    OlivieriNFBrittenhamGM. Iron-chelating therapy and the treatment of thalassemia. Blood1997;89:739761.

  • 18.

    PayneKADesrosiersMPCaroJJ. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion2007;47:18201829.

    • Search Google Scholar
    • Export Citation
  • 19.

    KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:5257.

    • Search Google Scholar
    • Export Citation
  • 20.

    RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:8693.

    • Search Google Scholar
    • Export Citation
  • 21.

    SloandEWuCGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:25052011.

    • Search Google Scholar
    • Export Citation
  • 22.

    The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfus Med Rev2005;19:6678.

  • 23.

    CremieuxPYBarrettBAndersonKSlavinMB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol2000;18:27552761.

  • 24.

    ShanderAHofmannAGombotzH. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol2007;21:271289.

    • Search Google Scholar
    • Export Citation
  • 25.

    CatlinACowanCHartmanMHefflerS. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood)2008;27:1429.

    • Search Google Scholar
    • Export Citation
  • 26.

    BrownMLYabroffKR. Economic impact of cancer in the United States. In: Schottenfeld D Fraumeni JF eds.Cancer Epidemiology and Prevention. 3rd ed.New York: Oxford University Press; 2006:202214.

    • Search Google Scholar
    • Export Citation
  • 27.

    BrownMLRileyGFSchusslerNEtzioniR. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care2002;40(8 Suppl):IV-104117.

    • Search Google Scholar
    • Export Citation
  • 28.

    YabroffKRWarrenJLBrownML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol2007;4:643656.

  • 29.

    KudererNMDaleDCCrawfordJ. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer2006;106:22582266.

    • Search Google Scholar
    • Export Citation
  • 30.

    LymanGHBerndtERKallichJD. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health2005;8:149156.

  • 31.

    BerndtECrownWKallichJ. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics2005;23:183192.

    • Search Google Scholar
    • Export Citation
  • 32.

    McKoyJMFitznerKAEdwardsBJ. Cost considerations in the management of cancer in the older patient. Oncology (Williston Park)2007;21:851857; discussion 858 860 862 passim.

    • Search Google Scholar
    • Export Citation
  • 33.

    LiouSYStephensJMCarpiucKT. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig2007;27:381396.

    • Search Google Scholar
    • Export Citation
  • 34.

    GossTFSzendeASchaeferC. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control2006;13Suppl:1725.

    • Search Google Scholar
    • Export Citation
  • 35.

    PavenskiKQuirtI. The real cost of iron chelation therapy. Transfusion2007;47:17511752.

  • 36.

    CMS. Hospital outpatient PPS. Available at: http://www.cms.hhs.gov/HospitalOutpatientPPS/01_overview.asp#TopOfPage. Accessed August 15 2008.

    • Search Google Scholar
    • Export Citation
  • 37.

    CMS. Medicare prescription drug plan cost estimator tool methodology. Medicare A. 2008; Available at: http://www.medicare.gov/medicarereform/Cost-Estimator-Tool-Methodology.pdf. Accessed August 15 2008.

    • Search Google Scholar
    • Export Citation
  • 38.

    MedicareB. Payment allowance limits for Medicare Part B drugs. Cigna Government Services. Available at: https://www.cignagovernmentservices.com/partb/coverage/fees. Accessed August 15 2008.

    • Search Google Scholar
    • Export Citation
  • 39.

    MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:75947603.

    • Search Google Scholar
    • Export Citation
  • 40.

    LymanGH. Time is money for both the healthy and the sick. Med Care2005;43:637639.

  • 41.

    RizzoJDSomerfieldMRHagertyKL. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol2008;26:132149.

    • Search Google Scholar
    • Export Citation
  • 42.

    LymanGHKudererNM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 43.

    CoslerLECalhounEAAgboolaOLymanGH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy2004;24:488494.

    • Search Google Scholar
    • Export Citation
  • 44.

    BaldiGD'IncaMSaltiniL. Cost/benefit relationship in 46 cases of myelodysplastic syndrome (RAEB and RAEB-T): a quality assurance analysis in clinical haematology. Haematologica1993;78:291296.

    • Search Google Scholar
    • Export Citation
  • 45.

    YabroffKRWarrenJLKnopfK. Estimating patient time costs associated with colorectal cancer care. Med Care2005;43:640648.

  • 46.

    KolataG. Co-payments go way up for drugs with high prices. New York Times. April 14 20082008:A1

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 90 90 11
PDF Downloads 37 37 6
EPUB Downloads 0 0 0